Prelude Capital Management, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Prelude Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $2.29 Million - $2.41 Million	-15,812 Reduced 30.79%	35,549 $5.37 Million
Q2 2022 Aug 15, 2022	BUY	$83.14 - $145.99 $4.27 Million - $7.5 Million	51,361 New	51,361 $7.48 Million
Q3 2020 Nov 16, 2020	SELL	$59.04 - $77.95 $125,637 - $165,877	-2,128 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$29.01 - $74.23 $61,733 - $157,961	2,128 New	2,128 $156,000
Q1 2020 May 15, 2020	SELL	$27.51 - $57.29 $126,023 - $262,445	-4,581 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$40.86 - $57.65 $140,844 - $198,719	3,447 Added 303.97%	4,581 $249,000
Q3 2019 Nov 14, 2019	SELL	$37.38 - $49.47 $588,174 - $778,410	-15,735 Reduced 93.28%	1,134 $47,000
Q2 2019 Aug 14, 2019	BUY	$39.79 - $67.01 $328,904 - $553,904	8,266 Added 96.08%	16,869 $739,000
Q1 2019 May 15, 2019	BUY	$34.52 - $53.29 $296,975 - $458,453	8,603 New	8,603 $443,000
Q4 2018 Feb 14, 2019	SELL	$29.75 - $42.9 $6,277 - $9,051	-211 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$32.79 - $43.0 $6,918 - $9,073	211 New	211 $8,000

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.